

GenePOC introduces new molecular diagnostic test

16 October 2017 | News

The test has been designed to identify streptococcus infection from direct vaginal or rectal swab samples at intrapartum.



GenePOC, a Canada based diagnostic devices maker, has introduced its GenePOC Group B Streptococcus (GBS) Direct Swab (DS) molecular test in Europe to reduce the risk of transmission from mother to newborn.

The test has been designed as a sensitive and accurate qualitative in-vitro diagnostic method to identify GBS from direct vaginal or rectal swab samples at intrapartum.

The point-of-care test will provide a precise assessment of the GBS colonisation status of the mother at the time of delivery, allowing better control of transmission risk, as well as lowering mortality and morbidity.

The company aims at working closely with the distribution partners to improve the standard of care while decreasing the occurrence of early onset Group B Streptococcal disease in infants.

The test is easy to use and enables analysis of up to eight samples in a single run and comes with an integrated process control to check sample processing and quality.